Company Overview and News

 
Risk of order book reductions seen with infrastructure job cuts

2018-10-05 theedgemarkets
Construction sector Maintain neutral: The outlook for the construction sector remains challenging as the federal government is reviewing ongoing infrastructure projects to reduce costs by 20%-33%. Projects that could be affected include the Klang Valley mass rapid transit Line 2 (MRT2) and light rail transit Line 3 (LRT3), Pan Borneo Highway (PBH) and Gemas-Johor Baru Electrified Double Tracking (EDT).
2852 9261 3204 5226 6238 5924 5263 5054 9679 5085 7078

 
Mohamed Hazlan’s hands likely to be full at Prasarana

2018-09-18 theedgemarkets
IN a maiden address via email to the staff of Prasarana Malaysia Bhd, new president and CEO Datuk Mohamed Hazlan Mohamed Hussain said, “Improved passenger and operational quality as well as sound financial management of infrastructure will be the pillars of Prasarana’s excellence.”
5239 5932 8591 3204 5054

 
TRC Synergy rises 6.82% on positive technicals

2018-07-13 theedgemarkets
KUALA LUMPUR (July 13): TRC Synergy Bhd shares rose 6.82% at mid-morning today, following a positive technical outlook on the stock.
5054

 
TRC Synergy may rebound higher, says RHB Retail Research

2018-07-13 theedgemarkets
KUALA LUMPUR (July 13): RHB Retail Research said TRC Synergy Bhd may rebound higher after it continued holding above the 41 sen support.
5054

1
Construction firms to benefit from infrastructure spending

2018-04-16 thestar.com.my
Rakuten Trade Sdn Bhd vice-president (research) Vincent Lau told StarBiz that the different packages of work for the Pan-Borneo Highway in Sabah, the East Coast Rail Link (ECRL), and MRT 3 would be rolled out soon
5253 5054 6874 0151

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...